Evidence map›Paper›PMID 20049732›Full record

ArticleEMBO molecular medicine2009

Converting cancer mutations into therapeutic opportunities.

Tom O'Brien, David Stokoe

Open access · goldAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Tom O'BrienDepartment of Cell Regulation, Genentech Inc, South San Francisco, CA, USA.
David Stokoe

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the use of synthetic lethality has been around for decades in model organism studies, it has only recently been applied to cancer therapy and judging by recent results, with great success. Following on a recent paper that demonstrates the clinical application of this strategy (Fong et al, 2009), Chris Lord and Alan Ashworth further explore the approach and show that poly(ADP-ribose) polymerase (PARP) inhibitors such as Olaparib can selectively target cancer cells defective in phosphatase and tensin homologue (PTEN, Mendes-Pereira et al, 2009) and that methotrexate is selectively lethal to MutS-homologue-2 (MSH2)-deficient tumour cells (Martin et al, 2009).

Indexed as

Antimetabolites, AntineoplasticGene Expression Regulation, NeoplasticHumansMethotrexateMutationMutS Homolog 2 ProteinNeoplasmsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPTEN PhosphohydrolaseAntimetabolites, AntineoplasticMethotrexateMSH2 protein, humanMutS Homolog 2 ProteinolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPTEN Phosphohydrolase

Identifiers

PMID20049732
PMCPMC3378146
OpenAlexW2136432514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.